YARW — Yarrow Bioscience, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1566044 ·
Last close
$22.52
Market Cap
—
52W High
$44.28
52W Low
$9.03
ADV30
134,460
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 97,000 | — | -3,102,000 | -3,007,000 | 23,604,000 | 22,925,000 | 1,542,000 |
| Mar 2026 | 0 | — | -2,862,000 | -2,745,000 | 27,950,000 | 26,351,000 | 1,527,000 |
| Dec 2025 | 0 | — | -994,000 | -70,994,000 | — | — | — |
| Jun 2025 | 69,000 | — | -7,542,000 | -5,755,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-73,503,000
Investing CF
—
Financing CF
$99,854,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-73,739,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-3,856,000
Pretax Income TTM
$-73,739,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 1y)
Revenues vs Net Income (last 1y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | 100,407,000 | 71,547,000 | 28,860,000 | — |
TTM Snapshot
Revenues TTM
$3,471,000
NetIncome TTM
$39,264,000
OpCashFlow TTM
$0
Assets (Latest)
$30,160,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.03T | $1157.08 | — |
| JNJ | JOHNSON & JOHNSON | $638.00B | $264.74 | — |
| ABBV | AbbVie Inc. | $462.26B | $261.59 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
News headlines (Yahoo Finance, 1h cache)
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-09-14 20:05 · Yahoo
Yarrow Bioscience Announces Proposed Underwritten Public Offering
2026-09-10 20:03 · Yahoo
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
2026-09-11 01:11 · Yahoo
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 11:00 · Yahoo
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye D
2026-07-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.